Generic Products (December 2018)

Pharmacy Times, December 2018 Heart Health, Volume 84, Issue 12

Read about the new Generic Products featured in December.

MARKETED BY: Aurobindo Pharma Ltd

COMPARE TO: Norvir

INDICATION: FDA officials have approved ritonavir tablets as an AB-rated generic equivalent to AbbVie Inc’s Norvir to treat HIV. The drug works by preventing new viruses from becoming a mature form of HIV. Ritonavir does not cure HIV but may reduce illnesses and symptoms related to the viral infection and prevent the progression to AIDS.

DOSAGE FORM: Tablets

FOR MORE INFORMATION: aurobindousa.com

ESMOLOL HYDROCHLORIDE IN SODIUM CHLORIDE INJECTION

MARKETED BY: Mylan N.V.

COMPARE TO: Brevibloc

INDICATION: The FDA has approved Mylan’s esmolol hydrochloride in sodium chloride injection as a generic equivalent to Baxter’s Brevibloc. The injection is indicated for the short-term treatment of uncontrolled ventricular rates in supraventricular tachycardia, such as atrial fibrillation and atrial flutters, noncompensatory sinus tachycardia, and perioperative tachycardia with hypertension. The injection is available in a 2500-mg/250-mL single-dose plastic bag and a 2000-mg/100-mL single-dose plastic bag.

DOSAGE FORM: Injection

FOR MORE INFORMATION: mylan.com

ESTRADIOL VAGINAL INSERTS

MARKETED BY: Glenmark Pharmaceuticals Inc

COMPARE TO: Vagifem

INDICATION: Glenmark recently received FDA approval for its generic estradiol vaginal inserts to treat symptoms of menopause. The hormonal drug is inserted into the vagina to directly relieve the symptoms of vaginal dryness and to rebuild tissue. The inserts help relieve other symptoms associated with menopause, such as hot flashes, mood changes, and sleep problems.

DOSAGE FORM: Vaginal insert

FOR MORE INFORMATION: glenmarkpharma-us.com

SOFOSBUVIR 400 MG/ VELPATASVIR 100 MG AND LEDIPASVIR 90 MG/ SOFOSBUVIR 400 MG

MARKETED BY: Gilead Sciences, Inc

COMPARE TO: Epclusa and Harvoni

INDICATION: Gilead Sciences, Inc, announced its plans to launch generic versions of its costly treatments for hepatitis C virus (HCV). Sofosbuvir 400 mg/velpatasvir 100 mg will be generically equivalent to Epclusa, and ledipasvir 90 mg/ sofosbuvir 400 mg will be generically equivalent to Harvoni. The drugs are expected to be available by January 2019 at a list price of $24,000, allowing patients to save up to $2500 in out-of-pocket costs per therapy course. The generic launch will expand access to lifesaving drugs.

DOSAGE FORM: Tablet

FOR MORE INFORMATION: harvoni.com